Merck & Co's migraine hope promising in two more Phase III trials
This article was originally published in Scrip
Executive Summary
Merck & Co's novel antimigraine drug telcagepant (MK-0974) relieved pain symptoms consistently and induced fewer adverse events than a comparator, show results from two pivotal Phase III trials presented at the 14th International Headache Congress (IHC). The company will meet with the US FDA later this year to discuss the next steps in its development.